Congenital/Inherited CD59 Deficiency: A Systematic Review
- 1College of Medicine and Health Sciences, Arabian Gulf University, Manama P.O. Box 26671, Bahrain
- 2Department of Molecular Medicine, AlJawhara Center, College of Medicine and Health Sciences, Arabian Gulf University, Manama P.O. Box 26671, Bahrain
- 3Department of Pharmacology and Therapeutics, College of Medicine and Health Sciences, Arabian Gulf University, Manama P.O. Box 26671, Bahrain
Abstract
Background: Inherited CD59 deficiency is a rare autosomal recessive complement-mediated disorder caused by biallelic loss-of-function variants in the CD59 gene. It typically presents in infancy with Coombs-negative hemolytic anemia, relapsing demyelinating polyneuropathy, and recurrent ischemic strokes. Diagnosis is often delayed due to overlapping with more common neurological and hematological disorders. The present study was carried out to systematically review the literature on congenital CD59 deficiency, focusing on genotype–phenotype correlations, geographic distribution, clinical presentation, diagnostic approaches, and treatment outcomes. Methods: Eligible studies included case reports and case series of genetically or functionally confirmed inherited CD59 deficiency. Demographic, molecular, clinical, and therapeutic data were extracted and analyzed descriptively. Results: 20 reports included. Evidence remains mainly limited to case reports and small case series. The disorder demonstrates a severe and heterogeneous phenotype with predominant neuromuscular involvement, frequently associated with hematologic and cerebrovascular manifestations. Most reported cases originate from regions with high consanguinity, particularly the Middle East and Asia, suggesting possible founder effects and underrecognized prevalence. Exploratory analysis suggested a possible relationship between predicted variant functional impact and clinical severity. However, given the small and heterogeneous evidence base, this finding should be considered hypothesis-generating. Responses to conventional immunomodulatory therapies are variable and often transient. Eculizumab has shown clinical benefit in some patients, although treatment responses remain inconsistent. Conclusions: Congenital CD59 deficiency is a severe and underrecognized complement-mediated disorder with major diagnostic and therapeutic challenges. Current evidence remains insufficient to establish definitive genotype–phenotype correlations or standardized management strategies. Increased clinical awareness, early integration of functional and genetic testing, and further studies are needed to improve diagnosis and optimize treatment outcomes.
Related
- Congenital Unilateral Terminal Transverse Deficiency with a Rudimentary Distal Osseous Anlage in a Treatment-Naïve Adult: A Case Report.
- Gut microbiota and health-related quality of life in paediatric inherited metabolic disorders: a narrative review and conceptual framework
- SLC52A2-Related Riboflavin Transporter Deficiency in Non-Isolated Auditory Neuropathy: Evidence from a Chinese Cohort and a Global Variant Review
- Congenital fibrovascular pupillary membrane with secondary glaucoma and associated fundus anomalies: a case report and literature review.
- High‐Dose L‐Serine Supplementation During Febrile Decompensation in SARS1 Deficiency: A Case Report and Review of the Literature
BibTeX
@article{alwahiby2026congenitalinherited,
title = {{Congenital/Inherited CD59 Deficiency: A Systematic Review}},
author = {Lama Alwahiby and Lanah Alsuhim and Manal Alzahrani and Jalnar Albaloshi and Cristina Skrypnyk and Kannan Sridharan},
journal = {Journal of clinical medicine},
year = {2026},
month = oct,
doi = {10.3390/jcm15197751},
url = {https://europepmc.org/article/PMC/PMC13666367},
note = {CC BY},
}
RIS
TY - JOUR
TI - Congenital/Inherited CD59 Deficiency: A Systematic Review
AU - Lama Alwahiby
AU - Lanah Alsuhim
AU - Manal Alzahrani
AU - Jalnar Albaloshi
AU - Cristina Skrypnyk
AU - Kannan Sridharan
PY - 2026
DA - 2026/10/01
JO - Journal of clinical medicine
DO - 10.3390/jcm15197751
UR - https://europepmc.org/article/PMC/PMC13666367
AB - Background: Inherited CD59 deficiency is a rare autosomal recessive complement-mediated disorder caused by biallelic loss-of-function variants in the CD59 gene. It typically presents in infancy with Coombs-negative hemolytic anemia, relapsing demyelinating polyneuropathy, and recurrent ischemic strokes. Diagnosis is often delayed due to overlapping with more common neurological and hematological disorders. The present study was carried out to systematically review the literature on congenital CD59 deficiency, focusing on genotype–phenotype correlations, geographic distribution, clinical presentation, diagnostic approaches, and treatment outcomes. Methods: Eligible studies included case reports and case series of genetically or functionally confirmed inherited CD59 deficiency. Demographic, molecular, clinical, and therapeutic data were extracted and analyzed descriptively. Results: 20 reports included. Evidence remains mainly limited to case reports and small case series. The disorder demonstrates a severe and heterogeneous phenotype with predominant neuromuscular involvement, frequently associated with hematologic and cerebrovascular manifestations. Most reported cases originate from regions with high consanguinity, particularly the Middle East and Asia, suggesting possible founder effects and underrecognized prevalence. Exploratory analysis suggested a possible relationship between predicted variant functional impact and clinical severity. However, given the small and heterogeneous evidence base, this finding should be considered hypothesis-generating. Responses to conventional immunomodulatory therapies are variable and often transient. Eculizumab has shown clinical benefit in some patients, although treatment responses remain inconsistent. Conclusions: Congenital CD59 deficiency is a severe and underrecognized complement-mediated disorder with major diagnostic and therapeutic challenges. Current evidence remains insufficient to establish definitive genotype–phenotype correlations or standardized management strategies. Increased clinical awareness, early integration of functional and genetic testing, and further studies are needed to improve diagnosis and optimize treatment outcomes.
SN - 2077-0383
ER -